Trial
NCT03288545
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Merck Sharp & Dohme LLC; Seagen Inc.
Condition
Carcinoma, Transitional Cell
Intervention
enfortumab vedotin (EV)
Why stopped
Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-24